JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Quidel Corp

Fechado

12.29 5.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.4

Máximo

12.47

Indicadores-chave

By Trading Economics

Rendimento

602M

-131M

Vendas

24M

724M

Margem de lucro

-18.062

Funcionários

6,500

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+78.34% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-483M

726M

Abertura anterior

6.43

Fecho anterior

12.29

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 de abr. de 2026, 23:08 UTC

Ganhos
Grandes Movimentos do Mercado

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 de abr. de 2026, 23:42 UTC

Conversa de Mercado

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 de abr. de 2026, 23:08 UTC

Conversa de Mercado

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 de abr. de 2026, 22:42 UTC

Conversa de Mercado

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 de abr. de 2026, 22:10 UTC

Ganhos

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 de abr. de 2026, 21:56 UTC

Ganhos

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 de abr. de 2026, 21:44 UTC

Ganhos

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 de abr. de 2026, 21:43 UTC

Ganhos

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de abr. de 2026, 20:39 UTC

Ganhos

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

78.34% parte superior

Previsão para 12 meses

Média 20.67 USD  78.34%

Máximo 30 USD

Mínimo 15 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

1

Comprar

3

Manter

1

Vender

Informação Financeira

Custos administrativos e de venda

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

Resultado Operacional

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat